The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Sign Up to like & getrecommendations! Published in 2017 at "Nature"
DOI: 10.1038/nature21702
Abstract: Chronic myeloid leukaemia (CML) is driven by the activity of the BCR–ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of patients treated with imatinib surviving… read more here.
Keywords: inhibitor; abl1; kinase; bcr abl1 ... See more keywords